50 results about "Ginsenoside CK" patented technology

The invention discloses a method for preparing rare ginsenoside CK from transformed ginsenoside Rb1 and a use thereof. Ginsenoside Rb1 is transformed into rare ginsenoside CK by beta-glucosidase produced by bifidobacteria and a conversion rate is in a range of 62-68%. The transformed rare ginsenoside CK has very polarity, can be easily absorbed by the human body, and can enter into liver by blood circulation so that metabolism is finished and unique pharmacological effects are obtained. Bifidobacteria are edible probiotics and can produce glycosidase with high catalysis activity, selectivity and stability. The beta-glucosidase produced by bifidobacteria can transform ginsenoside Rb1 into rare ginsenoside CK, and has the advantages of high conversion rate, less side effect, safety, reliability, no pollution and industrial production easiness. The method has a low cost, simple processes and a short conversion period. Beta-glucosidase produced by bifidobacteria has an important application value in preparation of rare ginsenoside CK and the method utilizes the application value.

The invention discloses a beta-glycosidase mutant and a coding gene thereof, and an application thereof in producing ginsenoside CK. The protein disclosed by the invention is named as lacS-mut, and is one of defined as the following items: 1) the protein is composed of amino acid residue sequence of a sequence 4 in the sequence table; 2) the protein is derived from the protein as defined in the item 1) by substituting and / or deleting and / or adding of one or several amino acid residues in the amino acid residue sequence of the sequence 4 in the sequence table, and has beta-glycosidase activity. Experiments prove that the beta-glycosidase mutant is obtained by mutating a wild type beta-glycosidase gene; compared with the wild type, the beta-glycosidase mutant has the advantage that the activity of the beta-glycosidase mutant in synthesizing the ginsenoside CK is obviously improved, and therefore the beta-glycosidase mutant has better industrial application prospect.

The invention provides a preparation method of ginsenoside CK and relates to a method for preparing 20-O-beta-D-glucopyranosyl-20-protopanoxadiol (ginsenoside CK) by fermenting and converting protopanoxadiol in a full-automatic fermentation tank by means of a bacterial strain. The method comprises the following steps: (1) culture of microorganisms; (2) fermentation and conversion of microorganisms; and (3) chromatographic separation and purification by macroporous resin to finally obtain a compound with the chemical name: 20-O-beta-D-glucopyranosyl-20-protopanoxadiol (ginsenoside CK).

The invention relates to a hyperthermophilic glycosidase mutant and an application thereof in preparation of ginsenoside CK, and belongs to the technical field of biotechnology engineering. An amino acid sequence of the hyperthermophilic glycosidase mutant is as shown in SEQ ID NO:2; and the hyperthermophilic glycosidase mutant is applied to preparation of rare ginsenoside CK. The hyperthermophilic glycosidase mutant has high heat resistance and stability; relatively high catalytic activity can still be kept after heat preservation at 70-80 DEG C for over 300 hours, and thus hyperthermophilic glycosidase mutant has the advantages of low storage and transportation cost, and low requirement standards on a cooling system of a reactor when applied to production; the kinetic reaction is accelerated; meanwhile, the hyperthermophilic glycosidase mutant has beta-glucosaccharase activity; glucosides of main protopanaxadiol type saponins C3 site and C20 site can be hydrolyzed on the basis that the saponin structure is not destroyed; and the hyperthermophilic glycosidase mutant is efficient, specific, few in byproducts, high in yield and the like, so that the Fpglula can be applied to industrial production of a rare ginsenoside Compound K.

The invention provides hair loss preventing and hair growth promoting shampoo and a preparation method thereof, and relates to the field of daily chemicals. The shampoo comprises the following raw materials of piroctone olamine, a radix gentianae extract, ginsenoside CK, diaminopyrimidine oxide, a ginseng root extract, a ginger root extract, a cordyceps militaris extract, a fructus forsythiae fruit extract, a radix sophorae yellowish sophora extract, arginine, Vit B6, a surfactant, a preservative, a hair conditioning agent, a chelating agent, a thickening agent, a pH-regulating agent, a flavoring agent, a freshener, a heat sensing agent and water. The shampoo is free from any hormones and illegal drugs, safe and healthy, and the components are in composite coordination, so that blood circulation can be promoted, hair mother cells are revived, estrogen secretion is restrained, scalp microenvironment is improved, inflammatory factor release is restrained, energy supply is reinforced, andfurther, the hair loss preventing effect is reinforced.

The invention relates to a method for preparing rare ginsenoside CK from protopanaxadiol ginsenoside through fermentation of microbacterium oxydans, in particular to a method for preparing 20-O-beta-D-glucopyranose-20-protopanaxadiol ginsenoside from protopanaxadiol ginsenoside Rb1, Rd and the like converted by utilizing fermentation of microbiological strains in a fully-automatic fermentation tank, belongs to the technical field of medicine, and comprises the steps: (1) fermentation cultivation of bacterial strains; conversion of raw materials Rb1, Rd and the like by utilizing fermented microorganisms and taking heteropolyacid HxYW12O40.nH2O with a Keggin structure as a catalyst, wherein Y is selected from P, Si, Fe or Zn, x is 3 or 4, and n is a positive integer ranging from 0 to 30; (3) preparative chromatographic separation and purification of conversion products, so as to finally obtain a compound with the chemical name being 20-O-beta-D-glucopyranose-20-protopanaxadiol ginsenoside.

The invention discloses a method for synthesizing rare ginsenoside CK (compound K) through biotransformation of natural saponins. According to the method, Ganoderma sinensis is used as a fermentation bacterium for fermentation culture, the natural saponins are added to fermentation broth for continuous fermentation after fermentation is performed for at least three days, and the rare ginsenoside CK is obtained. The rare ginsenoside CK is obtained through fermentation of Ganoderma sinensis used as the fermentation strain and the natural saponins used as a substrate, the transformation rate is high, and the rare ginsenoside CK is safe and non-toxic; compared with other microorganisms, the medicinal and edible fungus is higher in safety and can produce more bioactive substances in the process of synthesis through biotransformation, and product popularization is easy.

The invention relates to the technical field of medical treatment, in particular to application of ginsenoside CK in the preparation of external drugs and health cosmetics to treat atopic dermatitis.OVA-sensitized (ovalbumin-sensitized) atopic dermatitis mouse models are established; filaggrin gene-deficient atopic dermatitis mice are selected; the two types of mice are fed with ginsenoside CK with different concentrations. The results show that ginsenoside CK can evidently reduce the scratching frequency of the OVA- sensitized AD (atopic dermatitis) model mice and reduce epidermal and dermalthickness of the mice; the therapeutic effect of a medium concentration group and that of the high concentration group are evidently higher than that of the low concentration group and that of a dexamethasone cream group; ginsenoside CK can reduce dermatitis score and scratching frequency of Ft mice and the expression of IL-4 at skin lesions of the Ft mice, the therapeutic effect of the medium concentration group is higher than that of the low concentration group and that of the high concentration group, and dexamethasone cream cannot improve atopic dermatitis type skin lesions with skin barrier dysfunction caused by filaggrin gene deficiency. The external drugs and health cosmetics made with ginsenoside CK herein have the advantages of good therapeutic effect and good safety.

The invention relates to a composition. The composition includes ginsenoside Rk1, ginsenoside Rg5, ginsenoside CK and a total ginsenoside ginseng root extract product; and the composition is an interleukin (IL)-6 conditioning agent. Applications of the composition in the preparation of drugs are also related.

The invention discloses a method for preparing rare ginsenoside CK through gene combination transformation and application of the rare ginsenoside CK. According to the invention, glycosidase generatedby using genes of bacillus subtilis str.168 and bifidobacterium breve 689b can be used, so that the ginsenoside Rc can be converted into the rare ginsenoside CK efficiently in vitro.

The invention relates to the field of biology, and discloses an enzyme, an encoding gene thereof, application of the enzyme and the encoding gene, and a method for preparing a ginseng saponin compound K. The invention particularly provides the enzyme, the encoding gene thereof, a recombinant carrier, expression box, transgenic cell line or recombinant bacterium containing the encoding gene, a composition with the enzyme as the active component, and application of the enzyme to degradation of a glycoside compound, and provides a method for preparing the ginseng saponin compound K. When used for degrading ginsenoside Rb3 and gynostemma saponin IX in notoginseng leaf total saponin, the enzyme probably can also hydrolyze glucose at the C3 site by acting on the xylose glycoside structure at the C20 site in ginsenoside Rb3 and gynostemma saponin IX, and therefore ginseng saponin CK is obtained, and the conversion rate of ginseng saponin CK is 84% or above.

The invention belongs to the technical field of medical technology, relates to a preparation method for increasing CK (Compound K) yield of ginsenoside, and in particular relates to a preparation method for increasing the CK yield of ginsenoside by increasing the yield of a converted product through adjustment and control in a microbial conversion process. According to the preparation method, the yield of the converted product and the concentration of a primer are improved through metabolic regulation. The preparation method comprises the steps of: reconstructing ultraviolet mutagenesis of a parental strain, culturing in a high-concentration pseudo-ginseng stem and leave saponin culture medium, sieving in a directional manner to obtain a strain resisting to 1-5% of the total saponins of the pseudo-ginseng stems and leaves. Through the strain mutagenesis and the metabolic regulation, the concentration of the primer and the yield of the converted product are improved obviously, the final conversion rate is up to 43.63%, and the yield of the Compound K of the ginsenoside is improved by more than 80%. The preparation method for increasing CK yield of ginsenoside has practical significance for the industrial application of the microbial conversion.

The invention relates to the field of gene engineering, and discloses glycosidase, a coding gene of the glycosidase and application of the glycosidase and the coding gene. Specifically, the inventionprovides the glycosidase, the coding gene of the glycosidase, a recombinant vector, an expression cassette, a transgenic cell line or recombinant bacteria containing the gene, and application of the glycosidase in degradation of glycoside compounds or preparation of medicated koji. When the glycosidase provided by the invention is used for degrading ginsenoside and / or gypenoside, ginsenoside CK can be obtained, and the conversion rate is relatively high.

The invention acquires the glycosyltransferase mutants SEQ ID NOs:3-6 with enhanced enzyme activity by directed evolution method. The mutants or expressing microorganisms thereof can efficiently catalyze the glycosyl transfer reaction of protopanaxadiol to prepare ginsenoside CK, and have industrial development and application prospects.

The invention relates to a novel technology for producing CK through enzymatic catalysis and oriented conversion by taking protopanaxadiol ginsenoside as a raw material and separating and purifying the CK. The technology specifically comprises the steps that the protopanaxadiol ginsenoside is dissolved into deionized water, the solution is put into a fermentation tank, and after N2 is introduced into the tank for protection, on-line sterilization is conducted for 20 min at 121 DEG C; a complex enzyme and a catalytic quantity of a heteopoly acid (HxYW12O40.nH2O) catalyst with a Keggin structure are quantitatively added, wherein a mixed enzyme prepared by mixing pectinase with cellobiase in different proportions is adopted as the complex enxyme, Y is selected from P, Si, Fe and Zn, x is 3 or 4, and n is a positive integer ranging from 0 to 30; oriented conversion is conducted under the corresponding conditions to obtain a large quantity of the CK product, and the product is collected and purified to obtain the CK with the purity of 90% or above. The method is high in yield, friendly to the environment and simple in aftertreatment, and a foundation is laid for industrialized production.

The invention provides a liver cancer targeted ginsenoside-carrying CK chitosan polymer micelle drug delivery system and a preparation method thereof. The drug delivery system comprises a targeting head group, a basic carrier and anticancer drug, the targeting head group is A54 polypeptide, the basic carrier is amphipathic polymer, the anticancer drug is ginsenside CK, the targeting head group isconnected with a hydrophobic end of the basic carrier through a connection group to form a drug delivery carrier, and the drug delivery carrier entraps ginsenoside CK to form the drug delivery system.The drug delivery system prepared by the method can obviously improve water solubility of ginsenside CK, can actively target liver cancer cells and is of important significance in clinical treatmentof liver cancer.

The invention discloses a preparation method of nano ginsenoside CK, and relates to the technical field of cosmetics. Each polymer micelle is prepared through a film hydration method: respectively weighing 100mg of PEG-PLA<2k / 2k>, 100mg of PEGPLA<5k / 5k> and 0-8mg of ginsenoside CK, adding 1-50mL of methanol to dissolve, carrying out reduced pressure rotary evaporation at 25-60 DEG C to form a uniform transparent film, adding 1-20mL of deionized water for oscillation, performing filtering through a 0.22[mu]m millipore filter membrane to obtain ginsenoside CK-loaded PEG-PLA nano micelles with different drug loading capacities, and subjecting the nano micelles for freeze-drying for later use. The nano ginsenoside CK is prepared, the water solubility of the nano ginsenoside CK is improved, theefficacy of the nano ginsenoside CK is expected to be enhanced, the whitening effect of the nano ginsenoside CK is studied, and the nano ginsenoside CK is expected to be used as a nano ginseng cosmetic in the cosmetic fields of whitening, wrinkle resistance, freckle removal and the like.

The invention discloses engineering bacteria of gynostemma pentaphylla glycosyl transferase, and a construction method and applications thereof. The gynostemma pentaphylla glycosyl transferase is capable of catalyzing protopanoxadiol to synthesize rare ginsenoside CK, and is named as UGTGp3. The invention also discloses a method used for synthesizing rare ginsenoside CK, and applications thereof. According to the method, heterologous expression of the glycosyl transferase gene of gynostemma pentaphylla is carried out in escherichia coli, and in vitro enzymatic reaction is adopted for functional identification. Relatively high signals are detected in ESI mass spectrometry and HPLC detection. The obtained rare ginsenoside CK is high in yield; less side product is generated; industrialized production is convenient to realize; and foundation is provided for gypenoside heterologous biosynthesis.

Firstly, the invention provides application of the ginsenoside composition in preparation of a medicine for preventing and treating alopecia by acting on hair follicle tissues. The ginsenoside composition is composed of ginsenoside Rg1, ginsenoside Re and ginsenoside CK, the ginsenoside Rg1 and the ginsenoside Re are main active components, and the ginsenoside CK is an auxiliary component. Secondly, the invention further provides application of the ginsenoside composition in preparation of a medicine for improving hair follicle tissue activity, the medicine is directly smeared or sprayed on scalp to promote hair follicles in a resting period to enter a regeneration period, and hair growth is promoted. Then, the invention further provides application of the ginsenoside composition in preparation of a medicine for improving the activity of the in-vitro cultured hair follicle tissue, the ginsenoside composition is prepared into a tissue culture solution to act on the in-vitro cultured hair follicle tissue, so that the activity of the cultured hair follicle tissue can be improved, and the survival rate of transplanted hair follicles is remarkably improved.

The invention discloses an engineering bacterium of a gynostemma pentaphyllum glycosyl transferase, and a construction method and an application thereof. The gynostemma pentaphyllum glycosyl transferase can catalyze protopanoxadiol to synthesize rare ginsenoside CK and is named as UGTGp4. The invention also discloses a method for synthesizing the rare ginsenoside CK and an application. A gene of the glycosyl transferase from gynostemma pentaphyllum is heterologously expressed in escherichia coli, and functional identification is performed through in-vitro enzymatic reaction. A product is detected to show relatively higher signals by ESI mass spectrometry and HPLC. The ginsenoside prepared by the method has the advantages of high yield, less by-product, easy industrialized production and the like, and a foundation is laid for heterologous biosynthesis of gypenoside.

The invention discloses an application of gynostemma pentaphyllum glycosyl transferase in synthesis of rare ginsenoside. The gynostemma pentaphyllum glycosyl transferase can be used for catalyzing protopanaxadiol to synthesize the rare ginsenoside CK. The name of the gynostemma pentaphyllum glycosyl transferase is UGTGp5. The invention also discloses a method for synthesizing the rare ginsenoside CK and an application. The application has the advantages that a gynostemma pentaphyllum glycosyl transferase gene is subject to heterologous expression in escherichia coli, and the function of enzymatic reaction in vitro is identified; after a product is subject to ESI (electro-spray ionization) mass spectrometry and HPLC (high performance liquid chromatography) detection, a higher signal is displayed. The prepared ginsenoside has the advantages that the yield rate is high, the number of byproducts is fewer, the industrialized production is easy, and the foundation is laid for the heterologous biosynthesis of saponin of gynostemma pentaphyllum.

The present invention provides an anti-tumor composition comprising rare ginsenosides Rk2, CK and PPT. The anti-tumor composition of the present invention comprises a therapeutically effective amountof ginsenoside Rk2, ginsenoside CK and ginsenoside PPT as active ingredients, and a pharmaceutically acceptable carrier, the rare ginsenoside pharmaceutical composition comprises ginsenoside Rk2, ginsenoside CK and ginsenoside PPT in a weight ratio of 1: (1-2): (1-2). Under the condition that the weight ratio of the ginsenoside Rk2 to the ginsenoside CK to the ginsenoside PPT is a specific ratio,in the anti-tumor composition, the ginsenoside Rk2, the ginsenoside CK and the ginsenoside PPT have a synergistic effect, and any two of the ginsenoside Rk2, the ginsenoside CK and the ginsenoside PPTalso have a synergistic effect.

The invention relates to the field of medicine, in particular to a medical use of ginsenoside CK. The ginsenoside CK can be used for preventing acute myocardial infarction.

The invention discloses a ginsenoside CK preparation method. According to the present invention, ginsenoside CK is prepared by using a mixed acid hydrolysis method, wherein the ginsenoside CK with thecontent of more than 98% is prepared through preparation of the total saponin of the leaves of Panax notoginseng, preparation of ginsenoside CK, purification and other steps; the conversion efficiency of the method is high, the conversion product is easily separated so as to remove the impurity, and the ginsenoside CK crude product with the content of more than 90% can be obtained by using the simple solvent treatment, such that the disadvantage that the ginsenoside CK can be obtained by repeatedly using the silica gel column and gel column chromatography method is avoided; and the method hasadvantages of low cost and high efficiency, and is suitable for industrial production and marketing application.

The invention relates to an application of ginsenoside CK in prevention and treatment of acute myocardial infarction.

The invention discloses an application of gynostemma pentaphyllum glycosyl transferase in synthesis of rare ginsenoside. The gynostemma pentaphyllum glycosyl transferase can be used for catalyzing protopanaxadiol to synthesize the rare ginsenoside CK. The name of the gynostemma pentaphyllum glycosyl transferase is UGTGp5. The invention also discloses a method for synthesizing the rare ginsenoside CK and an application. The application has the advantages that a gynostemma pentaphyllum glycosyl transferase gene is subject to heterologous expression in escherichia coli, and the function of enzymatic reaction in vitro is identified; after a product is subject to ESI (electro-spray ionization) mass spectrometry and HPLC (high performance liquid chromatography) detection, a higher signal is displayed. The prepared ginsenoside has the advantages that the yield rate is high, the number of byproducts is fewer, the industrialized production is easy, and the foundation is laid for the heterologous biosynthesis of saponin of gynostemma pentaphyllum.

Firstly, the present invention provides the use of the ginsenoside composition in the preparation of a medicine for preventing and treating hair loss by acting on hair follicle tissue. The ginsenoside composition is composed of ginsenoside Rg1, ginsenoside Re and ginsenoside CK, wherein ginsenoside Rg1 and ginsenoside Re are main active components, and ginsenoside CK is an auxiliary component. Secondly, the present invention also provides the application of the above-mentioned ginsenoside composition in the preparation of a drug for improving the activity of hair follicle tissue. Applying or spraying the drug directly on the scalp promotes the telogen hair follicles to enter a regeneration cycle and promotes hair growth. Again, the present invention also provides the purposes of the above-mentioned ginsenoside composition in the preparation of the medicine that improves the activity of the hair follicle tissue cultured in vitro, making the ginsenoside composition into tissue culture fluid and acting on the hair follicle tissue cultured in vitro can improve the activity of the hair follicle tissue cultured. activity, significantly improving the survival rate of transplanted hair follicles.

The invention relates to a ginsenoside CK derivative, a pharmaceutical composition containing the ginsenoside CK derivative and application of the ginsenoside CK derivative and the pharmaceutical composition.

The invention discloses an application of ginsenoside CK and Rh1 and a composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance, and relates to a medical application of the ginsenoside CK and Rh1 and the composition thereof. According to the application, in-vitro and in-vivo studies show that the ginsenoside CK and Rh1 and the composition thereof can regulate and control synthesis and degradation of epimatrix of hepatic stellate cells (HSC-T6) of mice, significantly improve the abnormal liver function, lipid metabolism disorders, abnormal glucose metabolism and hepatic fibrosis degree of the non-alcoholic fatty hepatic fibrosis mice, and has a development prospect for serving as the medicine of combination of non-alcoholic fatty hepatic fibrosis and insulin resistance.